Drug
Retinoid 9cUAB30
Retinoid 9cUAB30 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Completed2
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
completed250%
terminated250%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_1
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
NCT02876640
completedphase_1
Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers
NCT01935960
completedphase_1
Study of 9cUAB30 in Healthy Participants
NCT00896974
terminatedphase_1
Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers
NCT01336387
Clinical Trials (4)
Showing 4 of 4 trials
NCT02876640Phase 1
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
NCT01935960Phase 1
Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers
NCT00896974Phase 1
Study of 9cUAB30 in Healthy Participants
NCT01336387Phase 1
Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4